Q&A With Kate Dawson From Biogen: Tecfidera Continues To Show Positive Results For Multiple Sclerosis Patients

OCTOBER 14, 2015
Adam Hochron
Tecfidera has been on the market for a few years to help treat relapsing remitting multiple sclerosis and through extended studies and watching the market positive results have been seen by patients using the oral treatment.

Kate Dawson, MD, the Vice President of the US Medical Group for Biogen discussed continued reearch on the treatment during the annual ECTRIMS conference in Barcelona. 

Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.